Hologic : Launches Fluent® Fluid Management System for Hysteroscopic Procedures in EuropePDF Format ()

January 21, 2021

Download this Press Release PDF Format (opens in new window)

New Technology Simplifies and Streamlines Fluid Management for Healthcare Professionals

MARLBOROUGH, Mass., Jan 21, 2021 -- Hologic, Inc. (Nasdaq: HOLX) announced today the European launch of its new, CE-marked Fluent^® fluid management system, featuring innovations designed to provide healthcare professionals performing hysteroscopic procedures simpler, more effective fluid management.

The new system is designed to give clinicians clinical confidence by providing consistent intrauterine pressure and accurate fluid deficit readings. Its advanced technology is designed to help maintain consistent intracavity pressure and uterine distention and measure fluid deficit readings within +/- 50 mL.^{[i],[ii],[iii].}

'The Fluent system is the latest example of how Hologic offers best-in-class products in women's screening, diagnostics, and interventional areas based on insights into our customers' needs,' said Jan Verstreken, Hologic's Group President, International. 'This launch is a testament to how our strong customer partnerships and unique technological innovations enable us to provide healthcare professionals with solutions that optimise both diagnoses and treatment.'

To simplify hysteroscopic operations, the Fluent system features a single waste bag design and unique FloPak™ technology to effectively control fluid use throughout the procedure. An intuitive user interface provides step-by-step instructions for setup, disassembly and troubleshooting, and ultimately helps optimize workflow. In addition, large visual and audible alerts monitor fluid deficit, pressure, low fluid bags, and full waste bags to help keep procedures moving as efficiently as possible.

The Fluent system helps optimize and streamline hysteroscopic workflow in combination with a wide variety of hysteroscopic devices. Equipped with an integrated MyoSure^® controller, the Fluent system can be an all-in-one fluid management and tissue removal system. It is designed with fluid and vacuum systems that maximize the performance of the MyoSure system.

Hologic's MyoSure suite of products includes the MyoSure MANUAL, MyoSure LITE, MyoSure REACH, and MyoSure XL devices for tissue removal in a wide range of sizes and locations. To learn more about the MyoSure and Fluent suite of products, visit https://gynsurgicalsolutions.com/product/fluent-fluid-management.

About Hologic
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic, Fluent, MyoSure, The Science of Sure, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners.

Important Safety Information
The Fluent fluid management system is intended to provide liquid distension of the uterus during diagnostic and operative hysteroscopy, and to monitor the volume differential between the irrigation fluid flowing into and out of the uterus while providing drive, control and suction for hysteroscopic morcellators. The Fluent fluid management system may not be used to introduce fluids into the uterus when hysteroscopy is contraindicated. The system should not be used to remove pathologies from pregnant patients or patients exhibiting pelvic infection, cervical malignancies, or previously diagnosed endometrial cancer. For detailed benefit and risk information, please consult the Instructions for Use.

Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based. This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or email [e-mail].

Media Contact:
Jane Mazur
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
[e-mail]

Investor Contact:
Michael Watts
+1 858.410.8588
[e-mail]

[i] Hologic, Inc. Data on file, bench testing. DTP-00591

[ii] Hologic, Inc. Data on file, bench testing. DTP-00737.

[iii] Hologic, Inc. Data on file, bench testing. DTP-00548.

Categories:Press Releases